

1 Natural killer cell immunosuppressive function requires CXCR3-dependent redistribution within
2 lymphoid tissues.

3 Ayad Ali, Laura M. Canaday, H. Alex Feldman, Hilal Cevik, Michael T. Moran, Sanjeeth Rajaram,
4 Nora Lakes, Jasmine A. Tuazon, Harsha Seelamneni, Durga Krishnamurthy, Eryn Blass, Dan
5 H. Barouch, Stephen N. Waggoner

6 **SUPPLEMENTAL METHODS**

7 Mice: C57BL/6, *Cxcr3*^{KO}, B6.SJL-*Ptprca*^a*Pepcb*^b/BoyJ (Ly5.1), and B6.129S7-*Rag1*^{tm1.1Cgn}/J
8 (*Rag*^{KO}) mice were purchased from Jackson Laboratory (Bar Harbor, ME). SMARTA LCMV-
9 specific TCR transgenic mice (1) were a gift from Shane Crotty (La Jolla, CA) and bred to Ly5.1
10 mice in house. All mice were created or rigorously backcrossed onto the C57BL/6 background
11 prior to receipt. Male mice between 8 to 20 weeks of age were routinely utilized in experiments.
12 Mice were housed under barrier conditions and experiments performed under ethical guidelines
13 approved by the Institutional Animal Care and Use Committees of Cincinnati Children's Hospital
14 Medical Center. Staff were blinded to genotype and treatment status of experimental groups
15 during harvesting, processing, and data acquisition.

16 Virus and viral vector injections: Mice were infected with the Armstrong strain of LCMV via
17 intraperitoneal injection of 5×10^4 plaque forming units per mouse. Viral stocks were previously
18 generated in house (2) via propagation on BHK21 cells with titer determined using Vero cells
19 (3). Other mice were given an intraperitoneal injection of 3×10^7 plaque forming units of
20 adenovirus serotype 5 (Ad5)-LacZ (a gift from Jeff Molkentin, Cincinnati, OH) or 1×10^{10} viral
21 particles of Ad5-LCMV GP (from Dan Barouch, Boston, MA).

22 Mixed bone marrow chimeric mice: Mixed bone marrow chimeric (BMC) mice deficient in or
23 expressing CXCR3 were generated by admixing the donor bone marrow of *Rag*^{KO}*Cxcr3*^{WT}

24 (referred to as CXCR3^{WT}) or *Rag*^{KO}*Cxcr3*^{KO} (referred to as CXCR3^{KO}) mice at a 9:1 ratio with
25 bone marrow from wild-type Ly5.1 mice (4). In this mixture, NK cells and other innate
26 lymphocytes preferentially derive from *Rag*^{KO} precursors while the adaptive compartment (T and
27 B cells) can only develop from Ly5.1 precursors and as such are always *Cxcr3*^{WT}. Bilateral femur
28 bones of mice were harvested and stripped of muscle tissue using gauze sponges and blades.
29 Femur heads were cut to allow thorough flushing of the bone marrow with phosphate-buffered
30 saline into a petri dish using a 10 mL syringe topped with a 26G needle. Bone marrow cells were
31 counted using a hemocytometer and a bone marrow cell suspension was prepared to achieve
32 10x10⁶ cells/mouse. Recipient C57BL/6 mice were lethally irradiated (See Irradiation) prior to
33 intravenous injection of mixed bone marrow cells. A minimum of 16 weeks was allotted for
34 reconstitution prior to initiating experimental infections.

35 SMARTA transfer model: SMARTA mouse spleens were harvested and processed into single
36 cell suspensions (See Flow Cytometry) from which CD4 T cells were enriched by depletion of
37 non-CD4 T cells (Miltenyi Biotec, Germany). 5x10⁵ CD4 T cells were injected retro-orbitally into
38 CXCR3^{WT}, CXCR3^{KO} and NK cell-depleted mice 1 day prior to LCMV infection. Six days following
39 infection, spleens were harvested and SMARTA⁺ CD4 T cell numbers, activation status and
40 cytokine production were assessed by flow cytometry following in vitro LCMV-GP₆₄₋₈₀
41 (GPDIYKGVYQFKSVEFD) peptide stimulation (synthesized by 21st Century Biochemicals,
42 Marlborough, MA).

43 Irradiation: Irradiation of mice was performed using the J. L. Shepherd Mark I Cesium Irradiator.
44 Gamma irradiation was provided by Cesium 137 Source. Mice were placed into a rotating pie-
45 shaped holder to limit mobility and ensure equal irradiation. The pie-shaped holder was then
46 placed in the irradiator to deliver the required dose at a dose rate of 0.5 Gy per minute. The

47 optimal dose for hematopoietic ablation C57BL/6 mice is 11.75 Gy. All lethal doses/ablative
48 doses were delivered as two split exposures to limit non-hematopoietic toxicity. The split
49 exposures of 7.0 Gy for first exposure and 4.75 Gy for the second were separated by 3 hours. No
50 anesthesia or analgesics were used in this procedure.

51 Intravascular staining: Protocols for intravascular staining of lymphocytes (5) were adapted to
52 permit staining of NK cells. A few minutes prior to harvest, mice were anesthetized with
53 isoflurane then given retro-orbital injections of 1.2 μg of rat anti-NKp46-APC (29A1.4,
54 BioLegend, San Diego, CA) or goat anti-NKp46 (AF2225, R&D Systems, Minneapolis, MN)
55 antibodies in 200 μL saline per mouse. The injected antibody was allowed to circulate for no
56 more than 3 minutes prior to euthanasia. Spleens were then harvested, processed, and stained
57 as described under flow cytometry or prepared for confocal imaging as described under tissue
58 processing, sectioning and immunohistochemistry.

59 In vivo NK-cell depletion, recombinant IFN- α and IFNAR-1 blockade: One or two days before
60 infection, selective depletion of NK cells (6) was achieved through a single intraperitoneal
61 injection of 25 μg mouse anti-NK1.1 monoclonal antibody (PK136) or 25 μg of a control mouse
62 IgG2a isotype antibody (C1.18.4) produced by Bio-X-Cell (West Lebanon, NH). At time of Ad5-
63 GP or Ad5-LacZ vector immunization and for the two subsequent days, some mice were given
64 intraperitoneal injections of 8 $\mu\text{g}/\text{mouse}$ of recombinant interferon- α (752806, BioLegend, San
65 Diego, CA). Similarly, on days 0, 1, and 2 of LCMV infection, IFN-I signaling was blocked via
66 intraperitoneal injection of 400 μg of mouse anti-IFNAR-1 (MAR1-5A3) antibody from Bio-X-Cell
67 (West Lebanon, NH). In other experiments, mice were given one intraperitoneal injection of 100
68 μg anti-IFNAR-1 antibodies at time of LCMV infection.

69 RNA Isolation, cDNA synthesis and RT-qPCR: Spleens harvested from mice were processed
70 into single cell suspensions as described below (Flow Cytometry). 30 mg of whole spleen RNA
71 was extracted via 30 second homogenization in RLT lysis buffer containing 1% β -
72 mercaptoethanol per RNeasy kit (Qiagen, Germany). RNA was reverse transcribed into cDNA
73 using iScript cDNA synthesis kit (BioRad, Hercules, CA). Subsequent RT-qPCR was performed
74 using Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA) to detect *Cxcl9*
75 (Mm00434946_m1), *Cxcl10* (Mm00445235), *Cxcl11* (Mm00444662_m1), *Ifna9*
76 (Mm00833983_s1), *Ifnb1* (Mm00439552_s1) and *Gapdh* (Mm99999915_g1). cDNA was
77 combined with primers and Taqman Fast Advance master mix (ThermoFisher Scientific,
78 Waltham, MA) and amplified using Applied Biosystems 7500 Real-Time PCR and 7500
79 software v2.3.

80 Flow cytometry and in vitro peptide stimulation: Single-cell leukocyte suspensions were prepared
81 from spleens by mechanical homogenization of tissues between frosted glass microscope slides
82 (VWR, Radnor, PA) and filtration through a 70 μ m nylon mesh. Following lysis of red blood cells,
83 cells were plated at 2×10^6 /well in 96-well round-bottom plates, then either immediately subjected
84 to flow staining or first stimulated for 5 hours at 37°C with 1 μ M LCMV-GP₆₄₋₈₀ peptide
85 (GPDIYKGVYQFKSVEFD, 21st Century Biochemicals, Marlborough, MA) in the presence of
86 brefeldin A (BD Biosciences, San Jose, CA). Leukocytes were then washed and resuspended
87 in FACS buffer (Phosphate buffer saline + 5% fetal bovine serum + 0.5 mM EDTA) prior to
88 surface staining with the following antibodies: CD3e (145-2C11), CD19 (1D3), TCR β (H57-597),
89 NKp46 (29A1.4), NK1.1 (PK136), CD49b (DX5), CD4 (GK1.5), CD8 α (53-6.7), CD44 (IM7),
90 CD43 (1B11), TCRV α 2 (B20.1), CD45.1 (A20), CD45.2 (104), CXCR3 (CXCR3-173), Fas
91 (SA367H8) IgD (11-26c.2a), GL7 (GL7), NKG2D (1D11), KLRG1 (2F1/KRLG1), NKG2A

92 (16A11), CD94 (18d3), Ly49H (3D10), DNAM-1 (TX42.1), CD11b (M1/70), CD27 (LG.3A10),
93 CD25 (PC61) and granzyme B (GB11). All antibodies were purchased from BioLegend (San
94 Diego, CA) or BD Biosciences (San Jose, CA). Cells were surface stained for 15 to 30 minutes
95 at 4°C. For CXCR3 staining, cells were incubated at room temperature. Following staining, cells
96 were washed and fixed with BD fixation buffer (BD Biosciences, San Jose, CA) for 5 minutes at
97 4°C. Cells were washed twice and resuspended in 200 µL FACS buffer. For intracellular staining,
98 cells were washed and fixed with BD fixation/permeabilization buffer (BD Biosciences, San Jose,
99 CA) for 15 to 20 minutes at 4°C. Cells were then intracellularly stained with anti-IFN-γ (XMG1.2,
100 BD Biosciences, San Jose, CA) and anti-TNF (MP6-XT22, BD Biosciences, San Jose, CA) for
101 15 to 30 minutes at 4°C. Cells were then washed and resuspended in 200 µL FACS buffer and
102 analyzed on a BD LSR Fortessa cytometer.

103 Tissue processing, sectioning, and immunohistochemistry: Tissues to be analyzed by
104 fluorescence microscopy were placed into 4% formaldehyde solution for 5 hours followed by
105 overnight dehydration in a 30% sucrose (Sigma-Aldrich, St. Louis, MO) solution at 4°C. Samples
106 were washed with phosphate buffered saline prior to embedding within optimal cutting
107 temperature (OCT) media (Sakura Finetek, Maumee, OH) and frozen using a dry ice slurry in
108 100% ethanol and stored in -20°C. Tissues were sectioned (7-10 µm thick) using a cryostat
109 (Leica CM3050 S) and affixed to positively charged Denville slides (Thomas Scientific,
110 Swedesboro, NJ). Slides were dried at room temperature for 5 to 10 minutes preceding a 10
111 minute fixation in chilled 100% acetone at -20°C. Slides were subsequently dried at room
112 temperature for 5 to 10 minutes and washed twice in chilled phosphate-buffered saline before
113 being placed in saturation buffer containing 10% normal donkey serum (Sigma-Aldrich, St. Louis,
114 MO) and 0.1% Triton-X (Sigma-Aldrich, St. Louis, MO) in phosphate buffered saline for blocking


115 at room temperature for 45 minutes. Slides were incubated with a primary antibody cocktail
116 containing one or more of the following antibodies overnight at 4°C: 1:100 goat anti-NKp46 (R&D
117 Systems, Minneapolis, MN), 1:200 hamster anti-CD3e-AF594 or AF647 (500A2, BioLegend,
118 San Diego, CA) and rat anti-CD169-AF594 or AF647 (3D6.112, BioLegend, San Diego, CA).
119 The following day, slides were washed twice in chilled phosphate buffered saline. Subsequent
120 secondary antibody staining with 1:1000 donkey anti-goat AF488 (Abcam, United Kingdom) was
121 used for 2 hours at room temperature to reveal NKp46 primary staining. Slides were again
122 washed twice with chilled phosphate buffered saline, mounted with prolong diamond mounting
123 media (Thermo-Fisher Scientific, Waltham, MA), covered with a coverslip, and allowed to cure
124 overnight prior to imaging.

125 Confocal microscopy & NK-cell quantification: Confocal imaging was performed using a Laser
126 Scanning Nikon A1RSi Inverted Confocal Microscope with NIS Elements Confocal software. Z-
127 stacked tissue images were acquired through a 10X objective (Nikon Plan Apo λ) from which a
128 maximum intensity projection was generated prior to cell enumeration. Using tools available in
129 NIS Elements Analysis software and guided by CD169- and CD3-staining, borders around white
130 pulp (CD169 boundary) and T cell zones (CD3 boundary) were drawn. B220- and CD3-staining
131 were used to delineate borders when enumerating NK cells within lymph nodes. NK cells located
132 with these borders were enumerated using unbiased NIS Elements-derived algorithms and
133 plotted using GraphPad Prism (San Diego, CA). To calculate NK cell proportions within the white
134 pulp or T-cell zone, the total NKp46⁺ cells within the respective compartment were normalized
135 to total NKp46⁺ cells within the field of view. Brightness and contrast for each representative
136 image were adjusted equally across all channels using Photoshop CS6.

137 Statistics: Experimental results are consistently presented as the median with individual data
138 point spread. Statistical differences between control and experimental groups were calculated
139 using a one-way analysis of variance (ANOVA) with either the Holm-Šídák multiple comparison
140 test or a Dunnett's multiple comparisons test. When a confidence interval was not desired, the
141 Holm-Šídák multiple comparisons method was used to generate higher statistical power. A p-
142 value of less than 0.05 was considered significant. Graphing and statistical analysis were
143 routinely performed using GraphPad Prism (San Diego, CA). Researchers were blinded to
144 groupings and treatment during experimental measurements.

145 REFERENCES

- 146 1. Oxenius A, Bachmann MF, Zinkernagel RM, and Hengartner H. Virus-specific MHC-class
147 II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses
148 after viral infection. *European journal of immunology*. 1998;28(1):390-400.
- 149 2. Rydyznski C, Daniels KA, Karmele EP, Brooks TR, Mahl SE, Moran MT, et al. Generation
150 of cellular immune memory and B-cell immunity is impaired by natural killer cells. *Nature*
151 *communications*. 2015;6:6375.
- 152 3. Welsh RM, and Seedhom MO. Lymphocytic choriomeningitis virus (LCMV): propagation,
153 quantitation, and storage. *Curr Protoc Microbiol*. 2008;Chapter 15:Unit 15A 1.
- 154 4. Kurtulus S, Sholl A, Toe J, Tripathi P, Raynor J, Li KP, et al. Bim controls IL-15 availability
155 and limits engagement of multiple BH3-only proteins. *Cell death and differentiation*.
156 2015;22(1):174-84.
- 157 5. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al.
158 Intravascular staining for discrimination of vascular and tissue leukocytes. *Nature*
159 *protocols*. 2014;9(1):209-22.
- 160 6. Waggoner SN, Cornberg M, Selin LK, and Welsh RM. Natural killer cells act as rheostats
161 modulating antiviral T cells. *Nature*. 2012;481(7381):394-8.
162



163

164 **Supplemental Figure 1. Enumeration of NKp46⁺ NK cells within the splenic red pulp**


165 **following infection.** C57BL/6 mice (n=3-4/group) were infected with LCMV. At the indicated

166 time-point post infection, the number of NKp46⁺ NK cells were enumerated by confocal imaging

167 (see Figure 1) within the splenic red pulp defined by the region not bound the CD169

168 macrophages (5-12 follicles/mouse). Data are representative of two independent experiments.


169 Statistical differences determined by one-way ANOVA.



170



171 **Supplemental Figure 2. Ex vivo and in vivo NKp46 staining in blood and spleen NK cells.**

172 C57BL/6 mice (n=3) were infected with LCMV prior to intravascular staining at indicated time
 173 points. (A) Representative plots showing gating of NK1.1⁺ ex-vivoNKp46⁺ NK cells among
 174 CD3^{neg} TCR β ^{neg} CD8 α ^{neg} CD49b⁺ spleen cells while representative histograms show iv-NKp46
 175 staining on gated NK cells. (B) Representative plots show iv-NKp46 staining on NK cells (CD3^{neg}
 176 TCR β ^{neg} CD8 α ^{neg} CD49b⁺ NK1.1⁺ ex-vivoNKp46⁺) in blood. (C) Representative confocal images
 177 of spleen sections from uninfected mice and infected mice 3 days following LCMV injection
 178 visualizing NKp46⁺ (green) NK cells, B220⁺ (red) B cells and CD3⁺ (purple) T cells following
 179 staining with either donkey anti-goat-AF488 secondary antibody alone or re-stained with goat
 180 anti-mouse anti-NKp46 antibody ex vivo prior to donkey anti-goat secondary. Scale bars
 181 measure 500 μ m. Data are representative of two independent experiments.



183 **Supplemental Figure 3. Characterization of red pulp and white pulp-localized NK cells.** (A-
184 K) Three days following LCMV infection, C57BL/6 (n=4) mice were intravenously injected with
185 anti-NKp46 antibody three minutes prior to euthanasia to label splenic NK cells ($CD3^{neg} TCR\beta^{neg}$
186 $CD8\alpha^{neg} CD49b^{+} NK1.1^{+} ex-vivoNKp46^{+}$) in vascularized red pulp (iv-NKp46⁺) or white pulp (iv-
187 NKp46^{neg}) regions. Cells were stained for the indicated markers and assessed by flow cytometry.
188 The proportion of white pulp or red pulp NK cells expressing the indicated markers is shown.
189 Dotted line reflects expression level in uninfected mice. Data reflect one of two independent
190 experiments with statistical differences determined by Student's T-test.

191



192

193 **Supplemental Figure 4. Splenic NK cell migration during adenoviral vector immunization.**


194 C57BL/6 mice (n=3-4) were inoculated with Ad5-LaZ. (A) At indicated times post inoculation,

195 spleens were imaged to determine localization of NKp46⁺ NK cells (green) relative to CD169⁺

196 macrophages (red) and CD3 T cells (purple). (B) NK cells within the CD169-constrained white


197 pulp were enumerated in 5-12 follicles/mouse. Scale bars measure 100 μ m. Data reflect one of

198 two independent experiments with statistical differences determined by one-way ANOVA.



199

200 **Supplemental Figure 5. Role of type I interferons in NK-cell localization in draining lymph**
 201 **nodes.** C57BL/6 mice (n=3-4/group) were inoculated with Ad5-LacZ or LCMV and treated with
 202 either 8 μ g/mouse recombinant IFN- α or 400 μ g/mouse anti-IFNAR-1 antibodies. On day 3 of
 203 infection, NKp46⁺ (green) NK cells were enumerated within the B220⁺ (red) and CD3⁺ (purple)
 204 zones of inguinal (A-B) and mediastinal (C-D) lymph nodes. Data reflect one of two independent
 205 experiments with statistically significant differences determined by one-way ANOVA. Scale bars
 206 measure 100 μ m.



207

208 **Supplemental Figure 6. Reduced CXCR3 ligand expression following IFNAR blockade**

209 **during LCMV infection.** C57BL/6 mice (n=4/group) were treated or not with 100 μ g anti-IFNAR


210 antibodies prior to LCMV infection. Two days following infection, spleens were harvested, and

211 mRNA was extracted for RT-qPCR analysis of *Cxcl9*, *Cxcl10*, and *Cxcl11* expression levels.

212 Statistical differences determined by Student's T-test. Data are representative of two

213 independent experiments.

214



215


216 **Supplemental Figure 7. Confirmation of NK cell depletion and CXCR3 deletion in NK cells.**

217 Proportion of (A) CXCR3⁺ or (B) total CD49b⁺ NKp46⁺ NK1.1⁺ NK cells 7 days post-infection in

218 mixed CXCR3^{WT} or CXCR3^{KO} bone-marrow chimeras (n=7-12) depleted or not of NK cells. Data

219 pooled from two independent experiments with statistically significant differences determined by

220 (A) Student's T-test or (B) one-way ANOVA.



221

222 **Supplemental Figure 8. Model of CXCR3-dependent NK cell immunoregulatory activity**

223 **during infection.** Viral infection leads to NK cell localization within T cell-rich follicles wherein

224 they cull antiviral T cells, diminishing T cell cytokine responses and generation of T_{FH} cells. We

225 propose that loss of CXCR3 on NK cells impairs this localization, rescuing T cells from NK cell-

226 driven death. CXCR3 deletion thereby allows for increased T cell cytokine responses and T_{FH}

227 cell generation important for viral control and antibody production.